Physician

Reed Brian Mitchell, M.D.

According to 2025 Medicare claims, Reed Mitchell, M.D. (NPI: 1225091267) practices hematology/oncology in the Richmond, VA market, with the plurality of this provider's patient population coming from Henrico, VA. This provider's primary affiliated billing organization is VIRGINIA CANCER INSTITUTE INCORPORATED (NPI: 1730130980; TIN: 54-1066435) and primary practice location at 23229-8605. Mitchell is affiliated with the Advocate Physician Partners Accountable Care, Inc. (ACO ID: A1033) and Bryan Health Connect ACO, LLC (ACO ID: A4573), participating under the MSSP model.

Mitchell's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 599 traditional Medicare patients, billed 142,752 HCPCS/CPT codes, and received $2,222,161 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 1,458 prescription claims across 135 beneficiaries totaling $2,733,263 in drug costs, led by Revlimid (Lenalidomide). DME data shows 16 claims. Open Payments data shows 87 records totaling $7,507. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $1,387,205 and ending at $2,222,161. Concurrently, Part D prescription costs have risen steadily, from $1,111,505 to $2,733,263. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $4,174 to $1,299.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	818	88,210	$1,387,205
2016	936	130,271	$2,403,977
2017	1,049	161,932	$2,825,341
2018	843	136,177	$2,074,629
2019	584	56,114	$1,024,884
2020	704	119,864	$2,552,314
2021	789	120,948	$2,355,300
2022	784	127,064	$2,098,146
2023	656	151,692	$2,110,235
2024	599	142,752	$2,222,161

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	143	1,305	$1,111,505
2016	160	1,424	$1,406,328
2017	163	1,705	$2,028,368
2018	151	1,497	$2,011,388
2019	167	1,184	$2,152,878
2020	141	1,165	$2,102,593
2021	130	1,269	$2,011,688
2022	148	1,317	$2,131,250
2023	147	1,319	$2,297,282
2024	135	1,458	$2,733,263

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	52	$2,961
2016	N/R	11	$774
2017	N/R	17	$1,031
2018	N/R	14	$762
2019	N/R	11	$1,162
2020	N/R	14	$2,382
2021	N/R	N/R	N/R
2022	N/R	11	$787
2023	N/R	24	$914
2024	N/R	16	$1,104

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	101	292	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	106	253	$92
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	201	343	$63
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	98	187	$45
99212	Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more	105	134	$37

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	27	756	$551,058
Imbruvica	Ibrutinib	23	644	$373,130
Jakafi	Ruxolitinib Phosphate	18	540	$287,801
Lenalidomide	Lenalidomide	13	364	$196,535
Calquence	Acalabrutinib Maleate	14	420	$161,051

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	16	$1,104

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	86	$1,924	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$5,583	AstraZeneca UK Limited
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Reed Brian Mitchell, M.D.?

Tedicare shows public-source Medicare data for Reed Brian Mitchell, M.D. (NPI 1225091267), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Reed Brian Mitchell, M.D. have ACO affiliation data?

Reed Brian Mitchell, M.D. is shown with ACO affiliation data for Advocate Physician Partners Accountable Care, Inc. (MSSP, ACO ID A1033) and Bryan Health Connect ACO, LLC (MSSP, ACO ID A4573).

What billing organization is linked to Reed Brian Mitchell, M.D.?

Reed Brian Mitchell, M.D. is linked to VIRGINIA CANCER INSTITUTE INCORPORATED (billing NPI 1730130980) in the available physician profile data.

Does Reed Brian Mitchell, M.D. have Open Payments data?

Reed Brian Mitchell, M.D. has 87 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.